Literature DB >> 16248891

The galanin-R2 agonist AR-M1896 reduces glutamate toxicity in primary neural hippocampal cells.

Stefania Pirondi1, Mercedes Fernandez, Ralf Schmidt, Tomas Hökfelt, Luciana Giardino, Laura Calzà.   

Abstract

Galanin is a neuropeptide involved in a variety of biological functions, including having a strong anticonvulsant activity. To assess a possible role of galanin in modulation of glutamatergic synapses and excitotoxicity, we studied effects of a galanin receptor 2(3) agonist (AR-M1896) on several molecular events induced by glutamate administration in primary neural hippocampal cells. Exposure of cells, after 5 days in vitro, to glutamate 0.5 mM for 10 min caused morphological alterations, including disaggregation of beta-tubulin and MAP-2 cytoskeletal protein assembly, loss of neurites and cell shrinkage. When present in culture medium together with glutamate, 1 and 10 nM of AR-M1896 reduced these alterations. Moreover, AR-M1896 counteracted glutamate-induced c-fos mRNA and c-Fos protein up-regulation after 30-150 min, and 24 h, respectively. Massive nuclear alterations (Hoechst 33258 staining), observed 24 h after glutamate exposure, were also antagonized by AR-M1896 (0.1-100 nM) in a dose-dependent manner. These findings indicate that galanin, probably mainly through its type 2 receptor, interferes with events associated with glutamate toxicity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16248891     DOI: 10.1111/j.1471-4159.2005.03437.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  14 in total

1.  Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2).

Authors:  R Tofighi; B Joseph; S Xia; Z-Q D Xu; B Hamberger; T Hökfelt; S Ceccatelli
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

Review 2.  Neuroprotective role for galanin in Alzheimer's disease.

Authors:  Scott E Counts; Sylvia E Perez; Stephen D Ginsberg; Elliott J Mufson
Journal:  Exp Suppl       Date:  2010

Review 3.  Galanin in Alzheimer's disease: neuroinhibitory or neuroprotective?

Authors:  S E Counts; S E Perez; E J Mufson
Journal:  Cell Mol Life Sci       Date:  2008-06       Impact factor: 9.261

Review 4.  Regulation of neurological and neuropsychiatric phenotypes by locus coeruleus-derived galanin.

Authors:  David Weinshenker; Philip V Holmes
Journal:  Brain Res       Date:  2015-11-20       Impact factor: 3.252

5.  Galanin fiber hyperinnervation preserves neuroprotective gene expression in cholinergic basal forebrain neurons in Alzheimer's disease.

Authors:  Scott E Counts; Bin He; Shaoli Che; Stephen D Ginsberg; Elliott J Mufson
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  Brain galanin system genes interact with life stresses in depression-related phenotypes.

Authors:  Gabriella Juhasz; Gabor Hullam; Nora Eszlari; Xenia Gonda; Peter Antal; Ian Muir Anderson; Tomas G M Hökfelt; J F William Deakin; Gyorgy Bagdy
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

7.  Endogenous galanin protects mouse hippocampal neurons against amyloid toxicity in vitro via activation of galanin receptor-2.

Authors:  Caroline R Elliott-Hunt; Fiona E Holmes; Dean M Hartley; Sylvia Perez; Elliott J Mufson; David Wynick
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

8.  Activation of the galanin receptor 2 (GalR2) protects the hippocampus from neuronal damage.

Authors:  Caroline R Elliott-Hunt; Robert J P Pope; Penny Vanderplank; David Wynick
Journal:  J Neurochem       Date:  2007-02       Impact factor: 5.372

9.  Galanin receptor 1 deletion exacerbates hippocampal neuronal loss after systemic kainate administration in mice.

Authors:  P Elyse Schauwecker
Journal:  PLoS One       Date:  2010-12-13       Impact factor: 3.240

10.  A role for galanin in human and experimental inflammatory demyelination.

Authors:  David C Wraith; Robert Pope; Helmut Butzkueven; Heidi Holder; Penny Vanderplank; Pauline Lowrey; Michael J Day; Andrew L Gundlach; Trevor J Kilpatrick; Neil Scolding; David Wynick
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.